Wells Fargo & Company MN grew its holdings in La Jolla Pharmaceutical Company (NASDAQ:LJPC) by 23.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,937 shares of the biopharmaceutical company’s stock after buying an additional 3,167 shares during the quarter. Wells Fargo & Company MN owned approximately 0.08% of La Jolla Pharmaceutical worth $504,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Legal & General Group Plc increased its stake in shares of La Jolla Pharmaceutical by 11.6% in the second quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 462 shares in the last quarter. American International Group Inc. increased its stake in shares of La Jolla Pharmaceutical by 7.1% in the first quarter. American International Group Inc. now owns 8,571 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 568 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of La Jolla Pharmaceutical in the second quarter valued at $387,000. Credit Suisse AG acquired a new stake in shares of La Jolla Pharmaceutical in the first quarter valued at $391,000. Finally, Airain ltd acquired a new stake in shares of La Jolla Pharmaceutical in the second quarter valued at $522,000.

Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) opened at $34.88 on Monday. La Jolla Pharmaceutical Company has a 12-month low of $16.41 and a 12-month high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.05. analysts predict that La Jolla Pharmaceutical Company will post -4.93 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Wells Fargo & Company MN Increases Stake in La Jolla Pharmaceutical Company (LJPC)” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.watchlistnews.com/wells-fargo-company-mn-increases-stake-in-la-jolla-pharmaceutical-company-ljpc/1699293.html.

A number of analysts have recently weighed in on the company. Jefferies Group LLC restated a “buy” rating and issued a $40.00 target price on shares of La Jolla Pharmaceutical in a research note on Tuesday, October 3rd. Zacks Investment Research lowered La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Cowen and Company restated a “buy” rating and issued a $55.00 target price on shares of La Jolla Pharmaceutical in a research note on Friday, October 27th. Finally, Chardan Capital restated a “buy” rating and issued a $85.00 target price on shares of La Jolla Pharmaceutical in a research note on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. La Jolla Pharmaceutical has an average rating of “Buy” and a consensus target price of $52.00.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Want to see what other hedge funds are holding LJPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for La Jolla Pharmaceutical Company (NASDAQ:LJPC).

Institutional Ownership by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with Analyst Ratings Network's FREE daily email newsletter.